Re-186-Etidronate - Efficacy of palliative radionuclide therapy for painful bone metastases

Pain palliation with bone-seeking radiopharmaceuticals is an effective treatment modality in patients with advanced metastatic bone cancer. Several studies have shown encouraging clinical results of palliative therapy using Re-186-HEDP, with an overall reported response rate of +/- 71% for painful osseous metastasized prostate and breast cancer patients. Re-186-HEDP is a very potential isotope with numerous advantageous characteristics for this purpose. Myelosuppressive toxicity is limited and reversible, which makes repetitive treatment safe. However, individual studies are difficult to compare, and are hampered by the numerous and different methods used to assess clinical respons. Standardized clinical response assessment using the objective multi-dimensional pain evaluation model should therefore be implemented.